Over the years, GalChimia has become the leading synthetic organic chemistry CRO in Spain. Recently, the company decided to invest resources to their own R&D projects, some of them in a shared effort with other companies. As part of this R&D GalChimia has worked on developing new production processes for two high value Active Pharmaceutical Ingredients (API).
Eltrombopag Olamine has been developed by GlaxoSmithKline. Eltrombopag is marketed under the brand name Promacta in US and Revolade in EU. Originally developed for conditions that lead to abnormally low platelet counts, it has been approved for the treatment of thrombocytopenia and more recently for a subgroup of patient suffering aplastic anemia. Mechanistically, it is an agonist of the thrombopoietin receptor, and participates to increasing proliferation and differentiation of megakaryocytes and increasing circulating platelets. The patent of the product will expire in 2025.
Prasugrel has been developed by Daichii Sankyo. It is marketed under the brand name Effient in US and Efient in EU. It is used for the reduction of thrombotic cardiovascular events in acute coronary syndrome. Prasugrel binding to P2Y receptor and avoid ADP binding, consequently it irreversibly inhibits adenosine diphosphate-induced platelet aggregation. The patent of the product will expire in 2021.
GalChimia’s team has worked on improving the yields and purities, reducing synthetic steps and lowering costs of the route using different non-propietary technologies. Two optimized routes for the APIs are patented and available for out-licensing.